Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

Aussie shares rise for first time in new financial year
Markets

Aussie shares rise for first time in new financial year

The ASX200 finished up 0.3% after better-than-expected domestic retail sales data.

AAP 7:45am
Soft tissue repair company Aroa could unlock $1.6b market
Markets

Soft tissue repair company Aroa could unlock $1.6b market

A transformational year is predicted for Aroa with potential for maiden profit.

Pūkaki mega-lake never seriously considered
Markets

Pūkaki mega-lake never seriously considered

Officials' idea for a giant lake would have cost billions and had serious impacts.

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Graham Skellern 03 Jul 2024